Octodrine
 | |
| Clinical data | |
|---|---|
| Other names | DMHA; Ottodrina; Vaporpac; Amidrine; 2-Aminoisoheptane; 2-Amino-6-methylheptane; 1,5-Dimethylhexylamine; 6-Methyl-2-heptylamine; 6-Methyl-2-heptanamine[1] |
| Routes of administration | Oral, inhaled |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.008.047 |
| Chemical and physical data | |
| Formula | C8H19N |
| Molar mass | 129.247 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Octodrine (also known as Vaporpac or DMHA) is a stimulant drug whose pharmacology was studied in a dozen animal studies from the 1940s through the 1970s. These studies found that octodrine can increase blood pressure and cardiac output in animals. The drug was previously approved for use by the FDA as an inhalant (i.e., Vaporpac and Tickle Tackle Inhaler) and in Germany as an oral agent as part of a multicomponent medication (i.e., Ambredin and Ordinal), but is no longer available.[3]
DMHA has also been found as an adulterant in sports supplements and is sold online as a designer drug.[3] [4]
Related designer drugs[edit]
References[edit]
- ^ CID 10982 from PubChem
- ^ "DMHA in Dietary Supplements". FDA. March 6, 2023. Retrieved June 9, 2023.
- ^ a b Cohen PA, Travis JC, Keizers PH, Deuster P, Venhuis BJ (June 2018). "Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA)". Clinical Toxicology. 56 (6): 421–426. doi:10.1080/15563650.2017.1398328. PMID 29115866. S2CID 5193271.
- ^ "Designer Stimulants: What Athletes Should Know | USADA". 24 January 2019.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |